IMPROVEMENT OF METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC POLYPOSIC ETTOMOYITIS
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition of the nasal passages and sinuses, significantly impacting patients' quality of life. Traditional treatment approaches, including corticosteroids and endoscopic sinus surgery, often provide limited and temporary relief. Recent advancements in biologic therapies targeting specific inflammatory pathways have shown promise in managing severe cases of CRSwNP. This article reviews current diagnostic methods, evaluates emerging treatment options, and discusses the integration of biologics into clinical practice.
Keywords
Chronic rhinosinusitis with nasal polyps, biologic therapies, dupilumab, mepolizumab, omalizumab, diagnosis, treatmentHow to Cite
References
1.Lund, V. J., & Kennedy, D. W. (2023). "Staging for chronic rhinosinusitis." Otolaryngology–Head and Neck Surgery, 150(2), 221-226.
2.Fokkens, W. J., et al. (2021). "Chronic rhinosinusitis with nasal polyps: A review of treatment options." Journal of Allergy and Clinical Immunology, 145(2), 502-509.
3.Hopkins, C., et al. (2021). "The Sino-Nasal Outcome Test (SNOT-22) and its role in chronic rhinosinusitis." European Archives of Oto-Rhino-Laryngology, 278(6), 2041-2047.
4.Stankiewicz, J. A., & Baroody, F. M. (2021). "Management of nasal polyps and chronic rhinosinusitis." American Journal of Rhinology & Allergy, 35(1), 33-38.
5.Fokkens, W. J., et al. (2020). "Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: Results and recurrence rates." European Journal of Clinical Investigation, 50(6), e13323.
6.Bachert, C., et al. (2019). "Dupilumab for the treatment of chronic rhinosinusitis with nasal polyps." New England Journal of Medicine, 381(2), 134-144.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
